A study have revealed that activation of ADRB2 results in inhibition tumor cell growth, as well as induction of apoptosis and tumor regression, where this activation results in the inactivation of the Raf-1/Mek-1/Erk1/2 pathway by a cAMP-dependent activation of protein kinase A17. Here, MAPK3 is linked to neoplasm.